HALOZYME THERAPEUTICS, INC. (HALO): Results of Operations and Financial Condition
HALOZYME THERAPEUTICS, INC. (HALO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of
How this was made
The 30-second read
Why it matters
The key tradable items are the beat-and-raise guidance ranges, the scale of royalty growth, and the disclosed repurchase activity under an expanded authorization.
Market read
A primary 8-K beat-and-raise with explicit FY2026 guidance ranges and a large buyback program update typically drives estimate revisions and near-term momentum.
What to watch
Higher cost of sales from bulk rHuPH20 and increased amortization/R&D from acquisitions could pressure margins if partner product uptake slows.
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Total revenue increased 48% year-over-year to $481.0 million, royalty revenue increased 50% to $307.7 million, adjusted EBITDA increased to $328.8 million, and the Company raised all four full-year 2026 financial guidance ranges.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenueGAAP | $481.0 million | – | 48% |
| Royalty revenueGAAP | $307.7 million | – | 50% |
| Cost of salesGAAP | $79.2 million | – | – |
| Amortization of intangibles expenseGAAP | $29.5 million | – | – |
| Research and development expenseGAAP | $27.7 million | – | – |
| Selling, general and administrative expenseGAAP | $57.0 million | – | – |
| Operating incomeGAAP | $287.7 million | – | – |
| Net incomeGAAP | $229.9 million | – | – |
| EBITDAnon-GAAP | $321.9 million | – | – |
| Adjusted EBITDAnon-GAAP | $328.8 million | – | 46% |
| Diluted earnings per shareGAAP | $1.90 | – | – |
| Diluted earnings per sharenon-GAAP | $2.28 | – | – |
| Cash, cash equivalents, restricted cash and marketable securitiesother | $231.9 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Royalty revenueContinued sales uptake of ENHANZE® partner products that have launched since 2020, predominantly by VYVGART® Hytrulo by argenx and DARZALEX® SC Janssen in all geographies and contributions from other recently launched products. | $307.7 million | – | 50% |
full year 2026 outlook
- Revenue$1.835 billion to $1.910 billion
- NoteTotal revenue growth of 31% to 37% over 2025 total revenue
- NoteRevenue from royalties of $1.220 billion to $1.245 billion
- NoteRoyalty revenue growth of 41% to 43% over 2025
- NoteAdjusted EBITDA of $1.225 billion to $1.280 billion
- NoteAdjusted EBITDA growth of 86% to 95% over 2025, including new Hypercon™ and Surf Bio investments of approximately $60 million
- NoteNon-GAAP diluted earnings per share of $8.65 to $9.00
- NoteNon-GAAP diluted earnings per share growth of 108% to 117% over 2025
- NoteThe Company’s earnings per share guidance includes new Hypercon™ and Surf Bio investments of approximately $60 million and does not consider the impact of potential future share repurchases.
Capital returns
- In May 2026, the Company announced a new share repurchase program to repurchase up to $1.0 billion of its outstanding common stock by December 31, 2028.
- The Company expects to buy back at least $400 million of shares in 2026.
- During the second quarter of 2026, the Company repurchased 4.8 million shares for $332.8 million at an average price of $69.30 per share under the May 2026 and February 2024 share repurchase programs.
- The February 2024 share repurchase program was completed in June 2026.
What drove it
- The 48% year-over-year increase in total revenue was primarily driven by royalty revenue growth and an increase in product sales.
- Royalty revenue growth was primarily driven by continued sales uptake of ENHANZE® partner products that have launched since 2020, predominantly VYVGART® Hytrulo and DARZALEX® SC.
- The increase in cost of sales was primarily due to an increase in bulk rHuPH20 sales.
- The increases in amortization of intangibles expense and research and development expense were attributed to the acquisitions of Elektrofi, Inc. and Surf Bio, Inc.
- Halozyme signed five new ENHANZE® and Hypercon™ collaboration agreements through July, including agreements with Vertex, Oruka, GSK, Incyte and an undisclosed partner.
Concerns
- Selling, general and administrative expense increased primarily due to consulting and professional service fees, including litigation costs incurred in connection with patent infringement litigation, acquisitions and increased compensation expense.
- Full-year adjusted EBITDA and non-GAAP diluted earnings per share guidance include new Hypercon™ and Surf Bio investments of approximately $60 million.
- The Company’s earnings per share guidance does not consider the impact of potential future share repurchases.
What to watch
- Sales uptake of VYVGART® Hytrulo, DARZALEX® SC and other recently launched ENHANZE® partner products.
- Execution of the five new ENHANZE® and Hypercon™ collaboration agreements signed through July.
- The Phase 1 SC bioavailability study with ENHANZE® added to the ongoing ARGX-119 adimanebart program in the third quarter of 2026.
- Progress toward the expected repurchase of at least $400 million of shares in 2026.
- Delivery against full-year 2026 guidance for total revenue, royalty revenue, adjusted EBITDA and non-GAAP diluted earnings per share.
Balance sheet and cash flow
- Cash, cash equivalents, restricted cash and marketable securities were $231.9 million on June 30, 2026, compared to $145.4 million on December 31, 2025.
- The increase was primarily driven by cash generated from operations.
Analysis
Halozyme reported a strong second quarter ended June 30, 2026. Total revenue was $481.0 million, compared to $325.7 million in the second quarter of 2025, and royalty revenue was $307.7 million, compared to $205.6 million. The Company attributed the revenue increase to royalty growth and increased product sales. Royalty growth was led by continued uptake of ENHANZE® products launched since 2020, predominantly VYVGART® Hytrulo and DARZALEX® SC, alongside contributions from other recently launched products.
Profitability increased with revenue. Operating income was $287.7 million versus $202.4 million, net income was $229.9 million versus $165.2 million, and adjusted EBITDA was $328.8 million versus $225.5 million. GAAP diluted earnings per share was $1.90 versus $1.33, while non-GAAP diluted earnings per share was $2.28 versus $1.54. Cost of sales, amortization expense, research and development expense, and selling, general and administrative expense each increased versus the second quarter of 2025. The Company cited higher bulk rHuPH20 sales, the Elektrofi and Surf Bio acquisitions, consulting and professional fees including litigation costs, and compensation expense as drivers of the higher costs.
The Company expanded its collaboration pipeline, stating that it signed five new ENHANZE® and Hypercon™ agreements through July with Vertex, Oruka, GSK, Incyte and an undisclosed partner. The agreements broaden the potential future royalty base, including the first licensing of ENHANZE® for a nucleic acid therapeutic and potential applications involving antibody-drug conjugates. Partner developments included FDA approval of a supplemental Biologics License Application for VYVGART® Hytrulo with ENHANZE® and positive topline results for TAK-881 with ENHANZE® in Primary Immunodeficiency Disease.
Capital deployment was significant during the quarter. Halozyme repurchased 4.8 million shares for $332.8 million at an average price of $69.30 per share, and its February 2024 repurchase authorization was completed in June 2026. The Company has a new program to repurchase up to $1.0 billion by December 31, 2028 and expects to buy back at least $400 million in 2026. Cash, cash equivalents, restricted cash and marketable securities were $231.9 million on June 30, 2026, compared to $145.4 million on December 31, 2025, with the increase primarily driven by cash generated from operations.
Halozyme raised each of its full-year 2026 financial guidance ranges. The new outlook calls for total revenue of $1.835 billion to $1.910 billion, royalty revenue of $1.220 billion to $1.245 billion, adjusted EBITDA of $1.225 billion to $1.280 billion, and non-GAAP diluted earnings per share of $8.65 to $9.00. The adjusted EBITDA and earnings-per-share outlook includes new Hypercon™ and Surf Bio investments of approximately $60 million. The updated outlook does not consider the impact of potential future share repurchases.
Management, verbatim
We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues.
Dr. Helen Torley, President and Chief Executive Officer
Total revenue increased 48% year-over-year to $481 million, royalty revenue increased 50% to $308 million and adjusted EBITDA grew 46% to $329 million, reflecting the strength of our differentiated royalty business. Based on these record results, we are raising our full year 2026 financial guidance.
Dr. Helen Torley, President and Chief Executive Officer
Importantly, we are delivering on both our near-term and long-term growth objectives. The ENHANZE value proposition is attracting new partners and additional products from our current partners.
Dr. Helen Torley, President and Chief Executive Officer
Not in the filing
stated, not guessed- Gross margin
- Gross profit
- Operating cash flow
- Free cash flow
- Debt balance
- Dividend amount or dividend policy
- Product sales revenue amount
- Formal reportable segment revenue disclosures
- Prior-quarter comparisons for reported financial metrics
- Tax rate
- Full-year 2026 gross margin guidance
- Full-year 2026 operating expense guidance
- Full-year 2026 tax-rate guidance
- Previous release outlook section for actual-versus-prior-guidance comparisons
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Halozyme’s ENHANZE (and Hypercon) platform generates royalty revenue from partner-developed subcutaneous and other therapeutic products; the 8-K updates 2Q26 performance and full-year 2026 outlook.
Ticker impact
Halozyme reported 2Q26 results and raised full-year 2026 guidance, citing record revenue growth and expanding ENHANZE/Hypercon collaborations.
Bullish near-term bias as guidance raise and capital return (large buyback) reinforce upside to consensus estimates.
The filing is a primary disclosure (8-K) with specific quarterly results, explicit full-year guidance ranges, and a disclosed $333M 2Q buyback plus a new $1.0B repurchase authorization.
Market effects
Supports sentiment for royalty-based drug delivery platforms and partner-dependent biotech revenue models.
Primarily US-listed biotech sentiment; limited direct regional spillover beyond Nasdaq small/mid-cap growth.
Partner collaborations include multinational pharma (e.g., GSK, Janssen, Vertex), reinforcing global demand for subcutaneous delivery technologies.
Counterpoint
Guidance upside may already be partially priced given the magnitude of the beat and the number of collaboration announcements; execution risk remains in converting partner pipeline into royalty streams.
Key entities
- issuerHalozyme Therapeutics, Inc.
Reported 2Q26 results, raised FY2026 guidance, and disclosed new ENHANZE/Hypercon collaboration agreements plus share repurchases.
- technology_platformENHANZE
Halozyme’s drug delivery technology used in partner collaborations and product launches that drive royalty revenue.
- technology_platformHypercon
Halozyme’s technology used in collaborations (e.g., oncology targets) to support partner product development.
- partnerVertex Pharmaceuticals
Entered a global exclusive collaboration and license agreement for Hypercon (up to three targets), including a $15M upfront payment.
- partnerIncyte
Signed a global collaboration and license agreement to evaluate additional subcutaneous formulations using ENHANZE for INCA033989.
